GALIANT[*] study in more than 2,400 patients shows Galvus as effective as commonly prescribed TZD drugs when added to metformin[1] New pooled data show Galvus is associated with lower overall incidence of cardiovascular and cerebrovascular events, such as heart attacks and strokes, than placebo[2] and confirm good tolerability in patients with mild-to-moderate renal impairment[3] Patients tolerated Galvus better than TZDs and did not gain weight - a common side effect of other type 2 diabetes medicines[1] Galvus demonstrates strong efficacy in broad patient population with over 14,000 patients treated in clinical program to date ...
Anytime
